Medical Center Cologne
Sachsenring 83
50677 Cologne | Germany
Tel.: +49 221 788030
Fax: +49 221 78803250

TIPS

The possible role of the dendritic cells in the biological immune response against malignancies (solid tumors) was discovered and clinically investigated...
read more

The goal of hyperthermia in oncology is to induce a fever state that will activate the immune system, and destroy the cancer cells. ...
read more

Viscum Album Therapy



For thousands of years, European mistletoe has been used as a medicinal plant in many healing traditions.

Extracts from botanical mistletoe have been used in Europe for decades to support immune function in cancer just as in Asia many Chinese herbs are used to balance energy flow in the body.

Extracts of mistletoe are well-studied in Western science and hundreds of scientific articles have been published on practically all aspects of its clinical use. The clinical protocols for using mistletoe in cancer treatment were initially developed by Rudolf Steiner, PhD (1861-1925).

Since that time, pharmacological research and clinical studies have shown that it provides a broad spectrum of anti-tumor activities and restoration of the cellular immune system.

Mistletoe is currently the most prescribed anticancer medication used in northern and central Europe.
European mistletoe (Viscum album L.) grows on various species of trees found in northern and central Europe.

Unlike almost all other plants, it blooms during winter when there is frost and snow and the white berries ripen a year later under the same conditions.
This process appears to be dormant in many cancer patients, who typically report never having experienced a fever.

The mistletoe’s form, color, shape, and content of the plant and berries depend upon on the type of tree on which it grows. As a result, the ratio of various constituents in the plant can differ significantly, reflected in the different composition of glycoproteins, viscotoxins and other components in the host tree.

For example, mistletoe grown on species of tree such as the apple tree (Mali) is indicated for use in uterine, colon and breast cancer in women. Extracts from mistletoe grown in oak trees (Quercus) are used for prostate cancer and tumors of the gastro-intestinal tract in men.

Extracts from mistletoe grown in maple trees (Fraxini) are used for cancers of the lungs and respiratory tract, and extracts of pine tree mistletoe (Pini) are used in treating brain tumors.
Fully 70 percent of all cancer patients receive mistletoe preparations and it is usually paid for by the national health care systems, making mistletoe a more frequently prescribed anticancer medication than any other type of medication, includind immunotherapies such as interleukin-2, all forms of chemotherapy and angiogenesis inhibitors.

Mistletoe is provided as a simple subcutaneous injection twice a week, preferably in the early morning. 		Like dendritic vaccinations, the mistletoe extract needs to be injected in a series to evoke and maintain a significant immune response.

At the Medical Center Cologne, approximately 85 percent of patients receive mistletoe.

Usually, after some instruction, they find it easy to give themselves these injections, which are applied just beneath the surface of the skin using a small insulin syringe and a very fine needle. 		Initially, the injection is repeated every three days. In most protocols, mistletoe is injected subcutaneously twice a week, for a period of several months to several years.

Injections are typically applied in the morning, when the core temperature is lower.

Based on each patient’s progress, the injections may then be prescribed periodically at six-week intervals.



BACK
Back to therapies